Clinical Trials Browser

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Squamous Cell Carcinoma of Head and Neck

Colonic Neoplasms

Advanced Gastric Cancer

Metastatic Castration Resistant Prostate Cancer

Stomach Neoplasms

Small Cell Lung Carcinoma

Advanced Gastric Cancer

Neoplasm Metastasis

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Mouth Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Nasopharyngeal Neoplasms

Neoplasm Metastasis, Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Nasopharyngeal Carcinoma

Advanced Solid Tumor

Advanced Solid Tumor

Triple Negative Breast Neoplasms

Stomach Neoplasms

Small Cell Lung Carcinoma

Ovarian Neoplasms, Triple Negative Breast Neoplasms

Stomach Neoplasms

Uterine Cervical Neoplasms

Osteosarcoma, Drug-Related Side Effects and Adverse Reactions

Stomach Neoplasms

Triple Negative Breast Neoplasms

Thyroid Neoplasms

Recurrence, Gestational Trophoblastic Disease

Biliary Tract Neoplasms, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

Esophageal Neoplasms

Cholangiocarcinoma

Small Cell Lung Carcinoma

Stomach Neoplasms

Breast Neoplasms

Recurrence, Lymphoma, Large B-Cell, Diffuse

Quality of Life

Efficacy and Safety

Neoplasm Metastasis, Osteosarcoma

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Clinical Trials

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

SPARE-02

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

PASSION

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Poetry-1

Chemotherapy Combined With Apatinib and PD-1 Antibody

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Apatinib for the Elderly Advanced Gastric Cancer

First-line Chemotherapy for Recurrent Cervical Cancer

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

LANCET

Study of Apatinib in Patients With Differentiated Thyroid Cancer

GTN

ACABC

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

MK 01

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

ARCAP

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Dose-Escalation and Safety Trial of YN968D1

Effect of Rifampicin on the Pharmacokinetics of Apatinib